Tasquinimod: Additional Phase II data
Additional data from a double-blind, international Phase II trial in 206 asymptomatic, metastatic CRPC patients showed that oral tasquinimod led to median overall survival (OS) of 34.2 months vs. 30.2 months for placebo. In a subgroup of CRPC patients with bone metastases (n=136), median OS was 34.2 months for tasquinimod vs. 25.6 months for placebo. Additionally, time to symptomatic progression was significantly longer in patients treated with tasquinimod vs. placebo (p=0.039). Patients received once-daily placebo or 0.25 mg oral tasquinimod for the first 2 weeks followed by once-daily 0.5 mg for the next 2 weeks and once-daily 1 mg for the following 5 months. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...